Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy (Q47310444)

13 January 2018

title

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy (English)

1 reference

13 January 2018

1 reference

1 reference

1 reference

Santica M Marcovina

1 reference

13 January 2018

author name string

Dahong Yu

1 reference

13 January 2018

Susan J Murdoch

1 reference

13 January 2018

Shamik J Parikh

1 reference

13 January 2018

Alexander Cobitz

1 reference

13 January 2018

Hongzi Chen

1 reference

13 January 2018

John D Brunzell

1 reference

13 January 2018

language of work or name

English

0 references

publication date

1 December 2006

1 reference

13 January 2018

Diabetes and Vascular Disease Research

published in

1 reference

13 January 2018

volume

1 reference

13 January 2018

issue

1 reference

13 January 2018

page(s)

189-196

1 reference

13 January 2018

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

cites work

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

LDL subclass phenotypes and the insulin resistance syndrome in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Prospective Study of Small LDLs as a Risk Factor for Non–Insulin Dependent Diabetes Mellitus in Elderly Men and Women

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

The evolving role of inflammation in obesity and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, low-density lipoproteins in men (The Quebec Cardiovascular Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Use and abuse of HOMA modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.029

21 January 2018

Identifiers

DOI

10.3132/DVDR.2006.029

1 reference

13 January 2018

1 reference

13 January 2018